ImmunityBio Shares Fall 17.4% After Record $12.43 Intra-Day High
Shares plunged 17.4% to close at $9.54 after hitting an all-time intra-day peak of $12.43 as investors cashed in gains. Last year ImmunityBio reported a 671% revenue surge to $113M and narrowed its net loss by 15% to $351.4M on strong Anktiva sales.
1. Stock Movement
Shares fell 17.4% to $9.54 after climbing to an intra-day high of $12.43, as investors sold shares following recent gains on the rapid revenue growth story.
2. Financial Performance
For full-year 2025, ImmunityBio reported revenues of $113 million, up 671% from $14.7 million in 2024, driven by a 700% jump in net product revenues of Anktiva; net loss narrowed by 15% to $351.4 million.
3. Expansion and Pipeline
In Q4, revenues rose 407% to $38.28 million while net loss widened 4.6% to $61.9 million; the company secured regulatory approvals for Anktiva in 33 markets and plans three new clinical trials over the next three years.